Kush M. Parmar, M.D., Ph.D., is the Chairman of Homology Medicines’ Board of Directors and a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Arvinas, Audentes, Homology, scPharmaceuticals and CycloPorters. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and was Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO) and Pulmatrix (NASDAQ: PULM). He serves on the Scientific Advisory Council of Princeton University’s Department of Molecular Biology and for the Grace Wilsey Foundation and is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow at Harvard Medical School and completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.